Empowered Funds LLC Purchases New Position in Ardent Health, Inc. $ARDT

Key Points

• Empowered Funds LLC acquired 551,293 Ardent Health shares during the second quarter, worth approximately $5.4 million and representing a 0.39% stake. Other major investors, including BlackRock and Vanguard, also recently established or increased positions.
• Ardent Health’s latest quarter included $1.62 billion in revenue, exceeding estimates, but adjusted earnings of $0.12 per share fell short of the $0.18 consensus. The company provided fiscal 2026 EPS guidance of $0.78 to $1.15.
• Analyst sentiment is mixed, with the stock carrying an overall “Hold” rating and an average price target of $13.05 versus its recent price of $10.85. CFO Alfred Lumsdaine also bought 10,000 shares, increasing insider ownership to 1.90%.

Empowered Funds LLC acquired a new stake in shares of Ardent Health, Inc. (NYSE:ARDT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 551,293 shares of the company's stock, valued at approximately $5,425,000. Empowered Funds LLC owned 0.39% of Ardent Health as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of ARDT. Goldentree Asset Management LP raised its holdings in Ardent Health by 99.7% in the fourth quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company's stock worth $20,302,000 after purchasing an additional 1,150,000 shares during the period. BlackRock Inc. acquired a new position in shares of Ardent Health in the 2nd quarter valued at $21,415,000. Ameriprise Financial Inc. grew its holdings in shares of Ardent Health by 8.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,769,335 shares of the company's stock valued at $23,444,000 after buying an additional 134,513 shares during the period. Vanguard Group Inc. increased its position in shares of Ardent Health by 44.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,352,676 shares of the company's stock valued at $17,923,000 after buying an additional 416,348 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Ardent Health by 6.6% in the 3rd quarter. Millennium Management LLC now owns 1,269,605 shares of the company's stock valued at $16,822,000 after buying an additional 78,861 shares in the last quarter.

Insiders Place Their Bets

In other Ardent Health news, CFO Alfred Lumsdaine bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $8.81 per share, with a total value of $88,100.00. Following the completion of the transaction, the chief financial officer owned 329,183 shares in the company, valued at approximately $2,900,102.23. This trade represents a 3.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.90% of the company's stock.

Ardent Health Trading Down 1.0%

NYSE:ARDT opened at $10.85 on Tuesday. Ardent Health, Inc. has a twelve month low of $7.71 and a twelve month high of $15.48. The company has a quick ratio of 1.99, a current ratio of 2.10 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average price of $10.59 and a two-hundred day moving average price of $9.78. The company has a market cap of $1.53 billion, a P/E ratio of 19.73, a price-to-earnings-growth ratio of 3.07 and a beta of 0.70.

Ardent Health (NYSE:ARDT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.06). The business had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.59 billion. Ardent Health had a net margin of 1.22% and a return on equity of 10.35%. Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. As a group, analysts expect that Ardent Health, Inc. will post 0.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ARDT. The Goldman Sachs Group reiterated a "neutral" rating and set a $13.00 target price on shares of Ardent Health in a report on Thursday, August 6th. Guggenheim increased their price target on Ardent Health from $13.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. UBS Group raised their price target on Ardent Health from $13.00 to $13.50 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Royal Bank Of Canada lifted their price objective on Ardent Health from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Monday, August 10th. Finally, Wall Street Zen cut Ardent Health from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Ardent Health presently has an average rating of "Hold" and an average price target of $13.05.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source